Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

SOZO® Digital Health Platform Receives FDA Clearance for Sarcopenia Risk Assessment

18 August 2026 · By · Wire by Fusion42

Published

18 August 2026

Topic

opportunities

◆ Sectors

Digital Health

◆ Geography

United States

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 18 August 2026 · Fusion42 review

The SOZO® Digital Health Platform has received FDA clearance for its sarcopenia risk assessment tool, allowing it to be used as a clinically validated digital biomarker to identify patients at risk for muscle loss and related health issues in the United States.

This Wire brief sits within Fusion42's coverage of Digital Health.

◆ ◆ The Wire takeaway

Your digital health product just cleared a key US regulatory hurdle, opening access to clinical markets that require FDA approval. Now is the time to accelerate healthcare partnerships before competitors seize the clinical validation advantage.

◆ Coverage

1 source · 18 Aug 2026

◆ Related on Wire

◆ Topics

Digital Healthfda-clearancedigital-healthsarcopeniaregulatory-approvalhealthtech